AstraZeneca

Poster Nordic DISCOVER observationsstudie typ 2-diabetes

14 September 2016 14:30

Stora skillnader i vården av typ-2 diabetes i Danmark, Norge och Sverige enligt ny studie som presenteras på EASD

Kontrollen av blodsocker och kolesterol hos patienter med typ 2-diabetes är bättre i Danmark jämfört med i Norge och i Sverige enligt resultat från studien Nordic DISCOVER. Studien är den första nordiska jämförande långsiktiga studien av primärvårdens omhändertagande av patienter med typ 2-diabetes. Resultat presenteras för första gången på den europeiska diabeteskonferensen EASD, 14 september.

13 September 2016 14:30

Fördubblade sjukdomskostnader i Sverige för typ 2-diabetes under åren 2006 – 2014. Följdsjukdomar som stroke och hjärtinfarkt kostar allt mer

Sjukdomskostnaderna för behandling av patienter med typ 2-diabetes fördubblades i Sverige mellan åren 2006 och 2014 samtidigt som kostnaderna för diabetesläkemedel genomgående under perioden endast representerar fyra procent. Det visar resultat från den svenska studien DAISY som presenteras på den europeiska diabeteskonferensen EASD, den 13 september.

12 September 2016 08:05

AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure

First programme to assess potential cardiovascular and renal benefit of an SGLT-2i beyond diabetes

19 Juli 2016 15:38

ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES

AstraZeneca today announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.

27 Maj 2016 14:18

Positive CHMP opinion in EU for saxa/dapa (saxagliptin and dapagliflozin) for adults with type-2 diabetes

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. .

16 Oktober 2015 08:03

AstraZeneca receives complete response letter from US FDA for saxagliptin / dapagliflozin fixed-dose-combination

AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for the investigational fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adult patients with type 2 diabetes

17 September 2015 16:31

AstraZeneca presents positive pooled analysis demonstrating the effect of dapagliflozin on albuminuria in hypertensive patients with type 2 diabetes

AstraZeneca today announced findings from a new post-hoc analysis of two Phase III trials, in which dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, 5 and 10 mg/d demonstrated greater reductions on HbA1c and systolic blood pressure (SBP) in patients with type 2 diabetes

8 Juni 2015 13:04

New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin

Study also found no evidence of increased risk of hospitalisation for heart failure for DPP-4 inhibitors compared with sulfonylureas

6 Juni 2015 20:17

AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin, saxagliptin and metformin for type 2 diabetes

Data in oral presentation demonstrate that the investigational combination of dapagliflozin, saxagliptin and metformin resulted in statistically significant reductions in HbA1c in patients uncontrolled on saxagliptin and metformin

3 Juni 2015 08:03

AstraZeneca to present data demonstrating progress of its comprehensive diabetes portfolio at the American Diabetes Association 75th scientific sessions

AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentationat the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.

15 April 2015 08:03

FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® and KOMBIGLYZE® XR

AstraZeneca today announced that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13to 1(1 abstained; 15 total votes) that the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with

25 Mars 2015 08:04

AstraZeneca to collaborate with the Harvard Stem Cell institute in diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

Nyhetsarkiv